Biogen is handing over a staggering $350 million in cash for a partnership with Sangamo Therapeutics. The deal will leverage gene therapy to develop Alzheimer’s and Parkinson’s drugs.

Related Posts

• 

  The developer of Among Us are currently battling against a particularly pernicious spam attack that’s forced the studio to perform emergency maintenance. It started yesterday when players started experiencing the “Eris Loris” spam in their online matches.

• 

  Two years ago, reporter Tom Cardoso set out to write a story about sentencing. Instead, he found himself digging through mountains of data that painted a disturbing picture of Canadian prisons

• 

  Federal inmates’ risk assessments determine everything from where a prisoner is incarcerated to what rehabilitation programs they are offered. After controlling for a number of variables, The Globe found Black and Indigenous inmates are more likely to get wor…